MINKAI BIOMEDICAL
To benefit cancer patients
Providing Safe and Effective Comprehensive Immunotherapy
Technologies and Solutions for Cancer Patients Worldwide
Minkai Biomedical Group Limited collaborates with the world’s top biomedical R&D institutions and teams:
Focusing on the R&D, clinical translation, and commercialization of personalized peptide vaccines for cancer, and leveraging China’s robust peptide production capacity, Minkai Biomedical is committed to addressing the huge unmet demand for clinical-grade peptide vaccines, and providing safe and effective comprehensive immunotherapy technologies and solutions for cancer patients worldwide.
Company Mission:
To deliver personalized and precision-based immune diagnostic and therapeutic technologies, products, and solutions centered on peptide vaccines to cancer patients worldwide.
Corporate Vision:
5-Year Goal: To become a global technological benchmark enterprise in cancer immunotherapy.
10-Year Goal: To achieve worldwide commercial coverage of cancer peptide vaccines.
Core Team
Prof. Markus Maeurer
CSO
Inno Xie
CEO
Prof. Wang Zhe
CTO
CSO
Prof. Markus Maeurer
  • MD, PhD in Immunology, Fellow of the Royal College of Physicians (FRCP)
  • Head of Immunotherapy / Immunosurgery, Champalimaud Foundation
  • Senior Advisor to the UK Parliament, Italian Government, and Bill & Melinda Gates Foundation
  • Karolinska Hospital | Karolinska Institute MTC
  • Head of the Immunology Department & Chief Physician of the Allogeneic Stem Cell Transplantation Center
  • Professor of Infectious Diseases & Clinical Immunology
  • First Faculty of Medicine, University of Mainz
  • Full Professor | Full Professor of Biology and Infectious Diseases & Director of the Diagnostic Laboratory of Medical Microbiology
  • University of Pittsburgh Medical Center (UPMC)
  • Assistant Professor of Surgical Oncology and Immunotherapy
  • Researcher in the Department of Surgical Oncology
  • Published over 310 scientific articles, with 28 of them published in The Lancet series
  • Holds 9 patents, specializing in technologies for precise immune cell expansion and targeted epitope design, aimed at develop intelligent immunotherapies for solid tumor patients
  • Serves as a reviewer for various international funding agencies, governments, and high-impact journals
  • Founder of the ‘Alliance for Cancer and Infectious Disease Prevention and Control’(in collaboration with University College London)
CEO
Inno Xie
  • Ph.D. in Innovation Management, Politecnico di Milano
  • Dual EMBA Degrees from Tsinghua University and INSEAD
  • Bachelor of Arts (B.A.), Peking University
  • Visiting Scholar, Harvard Kennedy School
  • Shanghai Advanced Institute of Finance (SAIF)
  • Chief Advisor for China Programs, Harvard Kennedy School
  • Chief Advisor, Health and Wellness Research Center, Institute for Industry Research, Tsinghua University
  • Director, China Science and Technology Development Foundation
  • Chief Art Education Partner, ‘Beautiful China’
  • Strategically launched over ten private equity funds, focusing on empowering industries through finance
  • Founder of Xuanru Art, China’s largest contemporary ink wash art fund, and creator of multiple phenomen art IPs
CTO
Prof. Wang Zhe
  • Ph.D. in Molecular and Cell Biology | University of Alabama
  • Bachelor of Clinical Medicine, Shanghai Jiao Tong University School of Medicine
  • Visiting Professor | University of South China Center for the Future
  • Distinguished Professor | Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Researcher | National Engineering Research Center for Protein Drugs
  • Senior Scientific Consultant | iRepertoire. Inc
  • Vice Director, CSO | JITRI Research Institute for Immunotechnology
  • Founder, CSO | GS Medical Biotechnology Development Co., Ltd.
  • Researcher | UPMC et INSERM UMR S 938 CDR, France
  • Postdoc Research Fellow | University of Mississippi Medical Center, USA
  • Postdoc Research Associate | Stowers Institute of Medical Research, USA
Strategic Partners
The Champalimaud Foundation
Centers Under the Champalimaud Foundation
The Champalimaud Foundation
Located in Lisbon, Portugal, the Champalimaud Foundation is a world-renowned cancer treatment and research center, renowned for its advanced translational medicine, personalized therapeutic regimens, and interdisciplinary teamwork. As a pioneer in scientific research, the foundation is dedicated to exploring scientific discoveries that benefit humanity and establishing new knowledge standards.
Clinical Center and Research Center
The Clinical Center is a state-of-the-art medical, scientific, and technological institution composed of Multidisciplinary Pathology Units (MPUs). Here, physicians collaborate with specialists to develop personalized diagnostic and treatment plans for patients;
The Research Center is dedicated to conducting world-leading basic and translational research, with current efforts focused on neuroscience, physiology, and cancer.
1
/3
Center for the Unknown
Conducts basic and translational research through the development of research programs and the provision of exceptional clinical services, diagnosing and treating conditions ranging from neurological disorders to cancer.
2
/3
Botton-Champalimaud Pancreatic Cancer Center
Established through a collaboration between the Foundation and Mauricio and Charlotte Botton, this center is the world's first cancer facility dedicated simultaneously to research and treatment of pancreatic cancer and refractory tumors. Its GMP cell preparation laboratory ranks among the most advanced cell processing facilities in Europe and globally.

Integrating cutting-edge services and equipment to ensure patients' health and comfort, the center operates with state-of-the-art technological support, housing research laboratories, a day hospital, surgical suites, as well as inpatient and intensive care facilities. Embracing the Foundation's innovative and differentiated model, it seamlessly integrates science, clinical practice, and patient care through a translational approach that enables the interconnection of research and clinical activities.

The center brings together multidisciplinary expertise across surgery, clinical medicine, clinical trials, tumor immunology, bioinformatics, and computational biology to develop innovative therapies and clinical trials, aiming to provide groundbreaking and effective treatments for patients with refractory tumors.
3
/3
Contact Us
Your Name
Your Email
Inquiry Type
Message Consultation
Contact us immediately
We will serve you wholeheartedly
Our Email
media@mkbiomedical.com
Submit Now
Submission Failed
The email address is invalid. Please enter your correct email address!